Zenas BioPharma, Inc. Common Stock (ZBIO)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.90B
Last updated: Nov 17, 2026 at 11:06 AM ET
Zenas BioPharma, Inc. Common Stock (ZBIO) Competitors
The companies most similar to Zenas BioPharma, Inc. Common Stock are Xencor (XNCR), Vir Biotechnology (VIR) and Harmony Biosciences Holdings (HRMY). By market cap, Zenas BioPharma, Inc. Common Stock ranks 9th of the 13 companies on this page; Xenon Pharmaceuticals (XENE) is the largest at $3.98B.
Peer Comparison
ZBIO's ROIC of -104.3% is below the peer median of -18.7%, and its revenue growth of -100.0% is below the median of 0.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Zenas BioPharma, Inc. Common Stock (ZBIO) | $1.90B | N/A | 168.0x | 0.0% | -104.3% | -100.0% | 0.00% |
| Xencor Inc (XNCR) | $2.78B | N/A | 13.5x | -58.8% | -17.3% | 454.9% | 0.00% |
| Vir Biotechnology Inc (VIR) | $1.71B | N/A | 5.4x | -61.0% | N/A | 19582.0% | 0.00% |
| Harmony Biosciences Holdings (HRMY) | $1.98B | 9.6x | 1.9x | 18.0% | 13.7% | 12.3% | 0.00% |
| Nuvation Bio Inc (NUVB) | $1.41B | N/A | 6.7x | -67.4% | -18.7% | 242.6% | 0.00% |
| Beam Therapeutics Inc (BEAM) | $2.36B | N/A | 15.0x | -73.9% | -29.7% | -96.8% | 0.00% |
| Biohaven Ltd. (BHVN) | $2.09B | N/A | N/A | 0.0% | -315.9% | 0.0% | 0.00% |
| MBX Biosciences, Inc. Common Stock (MBX) | $2.78B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Xenon Pharmaceuticals Inc (XENE) | $3.98B | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Legend Biotech Corp (LEGN) | $3.39B | 266.5x | 2.3x | -0.0% | N/A | 32.0% | 0.00% |
| Vor Biopharma Inc (VOR) | $1.19B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Septerna, Inc. Common Stock (SEPN) | $2.03B | N/A | 20.3x | -61.3% | N/A | -12.2% | 0.00% |
| Sellas Life Sciences Group Inc (SLS) | $1.60B | N/A | N/A | 0.0% | N/A | -82.5% | 0.00% |
| Peer median | $2.06B | 138.0x | 6.7x | -0.0% | -18.7% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Zenas BioPharma, Inc. Common Stock, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Xencor Inc (XNCR) | Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of cytokine and monoclonal antibody therapies designed... | XNCR competitors |
| Vir Biotechnology Inc (VIR) | Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. | VIR competitors |
| Harmony Biosciences Holdings (HRMY) | Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and markets therapies for patients with rare neurological disorders. | HRMY competitors |
| Nuvation Bio Inc (NUVB) | Nuvation Bio Inc., a clinical-stage biopharmaceutical company, is focused on developing therapeutic candidates for oncology. | NUVB competitors |
| Beam Therapeutics Inc (BEAM) | Beam Therapeutics Inc., a biotechnology company, develops precision genetic drugs for patients with serious illnesses in the United States. | BEAM competitors |
| Biohaven Ltd. (BHVN) | Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops candidate products targeting neurological diseases and rare disorders... | BHVN competitors |
| MBX Biosciences, Inc. Common Stock (MBX) | MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment... | MBX competitors |
| Xenon Pharmaceuticals Inc (XENE) | Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, is dedicated to developing therapies to treat patients with neurological disorders... | XENE competitors |
| Legend Biotech Corp (LEGN) | Legend Biotech Corporation, a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of new cell therapies for oncology... | LEGN competitors |
| Vor Biopharma Inc (VOR) | Vor Biopharma, Inc., an early stage cell therapy company, develops hematopoietic stem cell (eHSC) therapies designed for cancer patients. | VOR competitors |
| Septerna, Inc. Common Stock (SEPN) | Septerna, Inc. is a cutting-edge biotechnology firm dedicated to transforming disease treatment through its advanced selective protein modulation platform. | SEPN competitors |
| Sellas Life Sciences Group Inc (SLS) | SELLAS Life Sciences Group, Inc., an advanced-stage biopharmaceutical company, focuses on the development of new cancer immunotherapies for various indications... | SLS competitors |
Frequently Asked Questions About ZBIO
Who are Zenas BioPharma, Inc. Common Stock's main competitors?
The companies most similar to Zenas BioPharma, Inc. Common Stock include Xencor (XNCR), Vir Biotechnology (VIR), Harmony Biosciences Holdings (HRMY), Nuvation Bio (NUVB) and Beam Therapeutics (BEAM), listed from the closest match.
Who is Zenas BioPharma, Inc. Common Stock's biggest competitor?
Xenon Pharmaceuticals (XENE) is the largest of the similar companies at $3.98B; Xencor (XNCR) is the closest match by business profile, size, sector and industry.
How does ZBIO stock compare with its competitors?
ZBIO's P/S is 168.0x against a peer median of 6.7x; its net margin is 0.0% against a peer median of -0.0%.
Which of Zenas BioPharma, Inc. Common Stock's competitors pays a higher dividend?
Zenas BioPharma, Inc. Common Stock pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Zenas BioPharma, Inc. Common Stock bigger than its competitors?
No. Zenas BioPharma, Inc. Common Stock is 9th by market cap among the 13 companies on this page; the largest is Xenon Pharmaceuticals (XENE) at $3.98B.
ZBIO pages: Overview, Earnings, Forecast, Financials, Competitors